Lupin receives USFDA nod for Lorazepam Oral Concentrate

Drug firm Lupin today said it has received US health regulator's approval to market

RELATED ARTICLES

its generic Lorazepam Oral Concentrate, used for treating anxiety disorders, in the American market.

Lupin Pharmaceuticals Inc, a subsidiary of Lupin, has received final approval from US Food and Drug Administration (USFDA) for its Lorazepam Oral Concentrate USP, Lupin Ltd said in a statement.

The Mumbai-headquartered firm's product is a generic version of Roxane Inc's Lorazepam Intensol and is indicated for the management of anxiety disorders or for the short- term relief of the symptoms of anxiety or anxiety associated with depressive symptoms, it added.

According to IMS MAT September 2012 sales data, Lorazepam Oral Concentrate had annual US sales of nearly $10.7 million.

Lupin scrip closed at Rs 594 on the BSE, down 0.21 per cent from its previous close.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Healthy bottomlines are nothing if not backed by a happy work force

    Trust technology firms to devise solutions for every situation.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Tushar Gandhi

Bapu vs Netaji, a needless row

Once again, a rivalry from the past has been raked ...

Purnendu Ghosh

Eyes are our best social navigators

Eyes have a rich vocabulary. They can not only ...

Bubbles Sabharwal

The bitter cold heart of life

Life has a heart just as we do. Most times ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture